Search Within

Shanu Modi

Formats
  1. Meeting Abstract (151)
  2. Journal Article (101)
  3. Review (11)
  4. Correspondence (2)
  5. Editorial (2)
  6. Research Letter (1)
Groups
  1. Breast Medicine Service (268)
  2. Department of Medicine (268)
  3. Solid Tumor Oncology Division (268)
  4. Survivorship Research (114)
  5. GSK Faculty (107)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (90)

More Groups

People
  1. Clifford Hudis (79)
  2. Larry Norton (53)
  3. Sarat Chandarlapaty (51)
  4. Sujata Patil (44)
  5. Chau Dang (42)
  6. Komal Jhaveri (35)

More People

Years
  1. 2025 (8)
  2. 2024 (23)
  3. 2023 (15)
  4. 2022 (19)
  5. 2021 (19)
  6. 2020 (21)

More Years

Publications
  1. Journal of Clinical Oncology (66)
  2. Cancer Research (50)
  3. Annals of Oncology (27)
  4. Breast Cancer Research and Treatment (14)
  5. Clinical Cancer Research (10)
  6. Clinical Breast Cancer (8)

More Publications

Publishers
  1. American Society of Clinical Oncology (68)
  2. American Association for Cancer Research (64)
  3. Oxford University Press (33)
  4. Elsevier Inc. (19)
  5. Springer (18)
  6. Nature Publishing Group (13)

More Publishers

Results (268)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane
    Journal Article

    Fornier, M. N.; Modi, S.; Panageas, K. S.; Norton, L.; Hudis, C.
    Cancer (2005)

    Fulltext@MSK | Save
  • Single-agent gemcitabine in the treatment of advanced breast cancer
    Journal Article

    Modi, S.; Seidman, A. D.
    Clinical Breast Cancer (2004)

    Fulltext@MSK | Save
  • Phosphorylated/activated HER2 (P-HER2) as a marker of clinical resistance to single agent taxane chemotherapy for meta-static breast cancer (MBC)
    Meeting Abstract

    Modi, S.; DiGiovanna, M. P.; Lu, Z.; Moskowitz, C.; Panageas, K. S.; Van Poznak, C.; Hudis, C. A.; Norton, L.; Tan, L.; Stern, D. F.; more...
    Proceedings of the American Association for Cancer Research Annual Meeting (2003)

    Fulltext@MSK | Save
  • Determinants of response to gefitinib (Iressa®, ZD1839) in patients with advanced breast cancer
    Meeting Abstract

    Iacobuzio-Donahue, C. A.; Albain, K.; Elledge, R.; Gradishar, W.; Hayes, D.; Rowinsky, E.; Hudis, C.; Pusztai, L.; Tripathy, D.; Modi, S.; more...
    Clinical Cancer Research (2003)

    Fulltext@MSK | Save
  • Incidence of amenorrhea (A) in breast cancer (BC) patients (pts) <= 40 years of age after paclitaxel (T)-based adjuvant chemotherapy (CT)
    Meeting Abstract

    Fornier, M. N.; Modi, S.; Hudis, C. A.
    Breast Cancer Research and Treatment (2002)

    Fulltext@MSK | Save
  • Open-label, phase II, multicenter trial of ZD1839 ('Iressa') in patients with advanced breast cancer
    Meeting Abstract

    Albain, K.; Elledge, R.; Gradishar, W. J.; Hayes, D. F.; Rowinsky, E.; Hudis, C.; Pusztai, L.; Tripathy, D.; Modi, S.; Rubi, S.
    Breast Cancer Research and Treatment (2002)

    Fulltext@MSK | Save
  • An update on epidermal growth factor receptor inhibitors
    Journal Article

    Modi, S.; Seidman, A. D.
    Current Oncology Reports (2002)

    Fulltext@MSK | Save
  • Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer
    Journal Article

    Modi, S.; Panageas, K. S.; Duck, E. T.; Bach, A.; Weinstock, N.; Dougherty, J.; Cramer, L.; Hudis, C.; Norton, L.; Seidman, A.
    Journal of Clinical Oncology (2002)

    Fulltext@MSK | Save